- Home
- RCUS vs NMZ Comparison
RCUS vs NMZ Comparison
Compare RCUS & NMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- NMZ
- Stock Information
- Founded
- RCUS 2015
- NMZ 2003
- Country
- RCUS United States
- NMZ United States
- Employees
- RCUS N/A
- NMZ N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- NMZ Finance/Investors Services
- Sector
- RCUS Health Care
- NMZ Finance
- Exchange
- RCUS Nasdaq
- NMZ Nasdaq
- Market Cap
- RCUS 1.2B
- NMZ 1.2B
- IPO Year
- RCUS 2018
- NMZ N/A
- Fundamental
- Price
- RCUS $12.24
- NMZ $10.61
- Analyst Decision
- RCUS Buy
- NMZ
- Analyst Count
- RCUS 8
- NMZ 0
- Target Price
- RCUS $20.71
- NMZ N/A
- AVG Volume (30 Days)
- RCUS 730.0K
- NMZ 356.8K
- Earning Date
- RCUS 11-05-2025
- NMZ 01-01-0001
- Dividend Yield
- RCUS N/A
- NMZ 5.08%
- EPS Growth
- RCUS N/A
- NMZ N/A
- EPS
- RCUS N/A
- NMZ N/A
- Revenue
- RCUS $262,000,000.00
- NMZ N/A
- Revenue This Year
- RCUS N/A
- NMZ N/A
- Revenue Next Year
- RCUS N/A
- NMZ N/A
- P/E Ratio
- RCUS N/A
- NMZ N/A
- Revenue Growth
- RCUS 6.07
- NMZ N/A
- 52 Week Low
- RCUS $6.50
- NMZ $8.26
- 52 Week High
- RCUS $18.98
- NMZ $11.14
- Technical
- Relative Strength Index (RSI)
- RCUS 66.38
- NMZ 71.37
- Support Level
- RCUS $11.30
- NMZ $10.54
- Resistance Level
- RCUS $12.05
- NMZ $10.66
- Average True Range (ATR)
- RCUS 0.58
- NMZ 0.09
- MACD
- RCUS 0.04
- NMZ 0.04
- Stochastic Oscillator
- RCUS 86.73
- NMZ 92.19
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The company's investment objectives is to provide current income exempt from regular federal income tax by investing predominantly in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories. It seeks to provide attractive monthly tax-free income, portfolio diversification and attractive after tax total returns. The fund invests in municipal securities that are exempt from federal income taxes.